Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL800636 | 0.81 | TDP1 (0.34) | TDP1ALDH1A1LMNAMAPTPTGS2 | |
| SCHEMBL25637524 | 0.78 | ECE1 (0.36) | ALDH1A1 | |
| SCHEMBL800668 | 0.77 | ALDH1A1 (0.30) | TDP1ALDH1A1LMNAMAPTPTGS2 | |
| SCHEMBL15604274 | 0.75 | EPHX1 (0.34) | ALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL15729731 | 0.74 | DPP4 (0.42) | TDP1ALDH1A1LMNAMAPTPTGS2 | |
| SCHEMBL10136465 | 0.73 | KDM4E (0.40) | TDP1ALDH1A1LMNAMAPTPTGS2 | |
| SCHEMBL12017871 | 0.73 | ALDH1A1 (0.43) | TDP1ALDH1A1LMNAMAPTPTGS2 | |
| SCHEMBL10140886 | 0.73 | CYP2D6 (0.50) | TDP1ALDH1A1LMNAMAPTPTGS2 | |
| SCHEMBL21393747 | 0.73 | — | — | |
| SCHEMBL13895432 | 0.73 | TERT (0.38) | TDP1ALDH1A1LMNAMAPTPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911412-B2 | Derivatized chitosan polymers and methods of treating vascular disorders | SYNEDGEN, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230181623-A1 | COMPOSITIONS AND METHODS OF USE FOR WOUND HEALING | SYNEDGEN, INC. | 2023-06-15 | — | — | US | disclosed |
| US-10022393-B2 | Methods for treatment or prevention of damage resulting from radiation, trauma or shock | SYNEDGEN, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20160022730-A1 | COMPOSITIONS AND METHODS OF USE FOR WOUND HEALING | SYNEDGEN, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160022564-A1 | ORAL FORMULATION OF POLYGLUCOSAMINE DERIVATIVES IN COMBINATION WITH A NON-FERMENTABLE SUGAR | SYNEDGEN INC (US) | 2016-01-28 | — | — | US | disclosed |
| US-8796460-B2 | Compounds for inhibiting KSP kinesin activity | Mercky Sharp & Dohme Corp. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20140080785-A1 | METHODS FOR TREATMENT OR PREVENTION OF DAMAGE RESULTING FROM RADIATION, TRAUMA OR SHOCK | SYNEDGEN, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20120070370-A1 | SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-03-22 | — | — | US | disclosed |
| US-8119780-B2 | Chitosan-derivative compounds and methods of controlling microbial populations | SYNEDGEN, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110171172-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | MERCK SHARP & DOHME CORP. | 2011-07-14 | — | — | US | disclosed |
| US-20110150757-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | MERCK SHARP & DOHME CORP. | 2011-06-23 | — | — | US | disclosed |
| US-20110123435-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | MERCK SHARP & DOHME LLC | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150757-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | KIF18B, KIF5B, KIF18A | TDP1 624/4885ALDH1A1 2246/4885LMNA 2708/4885 |
| US-20120070370-A1 | SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS | KIF2C, SKP1, KIF5B | TDP1 586/4885ALDH1A1 1081/4885LMNA 2576/4885 |
| US-20230181623-A1 | COMPOSITIONS AND METHODS OF USE FOR WOUND HEALING | PARG, ARGLU1, AREG | TDP1 3421/4885ALDH1A1 3165/4885LMNA 2017/4885 |
| US-10022393-B2 | Methods for treatment or prevention of damage resulting from radiation, trauma or shock | HMGB1, ELANE, SERPINB1 | TDP1 882/4885ALDH1A1 2079/4885LMNA 843/4885 |
| US-20110123435-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | KIF5B, KIF2C, KIFC1 | TDP1 434/4885ALDH1A1 2214/4885LMNA 2512/4885 |
| US-20160022730-A1 | COMPOSITIONS AND METHODS OF USE FOR WOUND HEALING | PARG, ARGLU1, AREG | TDP1 3421/4885ALDH1A1 3165/4885LMNA 2017/4885 |
| US-20140080785-A1 | METHODS FOR TREATMENT OR PREVENTION OF DAMAGE RESULTING FROM RADIATION, TRAUMA OR SHOCK | HMGB1, ELANE, SERPINB1 | TDP1 882/4885ALDH1A1 2079/4885LMNA 843/4885 |
| US-20110171172-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | KIF5B, KIF2C, KIFC1 | TDP1 509/4885ALDH1A1 1933/4885LMNA 2583/4885 |
| US-20160022564-A1 | ORAL FORMULATION OF POLYGLUCOSAMINE DERIVATIVES IN COMBINATION WITH A NON-FERMENTABLE SUGAR | FUT6, FUT5, PGLS | TDP1 3310/4885ALDH1A1 4166/4885LMNA 3204/4885 |
| US-11911412-B2 | Derivatized chitosan polymers and methods of treating vascular disorders | CHIA, CHI3L1, CHI3L2 | TDP1 2402/4885ALDH1A1 2896/4885LMNA 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.